STOCK TITAN

Bio-Techne (TECH) director granted 1,381 RSUs vesting 2027-29

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BIO-TECHNE Corp (TECH) director Amy E. Herr reported an indirect grant of 1,381 Restricted Stock Units on 2026-08-17, held through a significant other. Each unit represents a contingent right to receive one share of BIO-TECHNE common stock, vesting in three annual installments in 2027, 2028, and 2029.

The filing also lists existing option and RSU awards with various exercise prices from $53.60 to $120.46 and expiration dates through 2035, along with direct holdings of 2,680 common shares and 576 indirect common shares. No sales or option exercises are reported.

Positive

  • None.

Negative

  • None.
Insider Herr Amy E.
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Units F7, F11 1,381 $0.00 $0.00
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F2 -- -- --
holding Stock Option (Right to Buy) F3 -- -- --
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F4 -- -- --
holding Stock Option (Right to Buy) F5 -- -- --
holding Stock Option (Right to Buy) F6 -- -- --
holding Restricted Stock Units F7, F8 -- -- --
holding Restricted Stock Units F7, F9 -- -- --
holding Restricted Stock Units F7, F10 -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 2,239 shares (Indirect, By significant other); Stock Option (Right to Buy) — 14,283 shares (Indirect, By significant other); Stock Option (Right to Buy) — 6,192 shares (Direct); Common Stock — 2,680 shares (Direct); Common Stock — 576 shares (Indirect, By significant other)
Footnotes (11)
  1. F1. Fully vested.
  2. F2. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
  3. F3. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
  4. F4. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
  5. F5. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
  6. F6. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
  7. F7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  8. F8. 160 restricted stock units vest on 8/15/2027.
  9. F9. 38 restricted stock units vest on 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
  10. F10. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
  11. F11. 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029.
RSU grant 1,381 units Indirect Restricted Stock Units granted on 2026-08-17, each for one share of common stock
Direct common shares held 2,680 shares Direct ownership of BIO-TECHNE common stock after reported transactions
Indirect common shares held 576 shares Indirect ownership through significant other after reported transactions
Option exercise price range $53.6000–$120.4600 Exercise prices of reported stock options on BIO-TECHNE common stock
Earliest option expiration 2027-08-05 Expiration date for a stock option with $66.9700 exercise price, indirect ownership
Latest option expiration 2035-10-30 Expiration date for a stock option with $60.9600 exercise price, direct ownership
RSUs vesting 8/17/2027 460 units Portion of the 1,381 RSU grant vesting on 8/17/2027
RSUs vesting 8/17/2029 461 units Final tranche of the 1,381 RSU grant vesting on 8/17/2029
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with specified exercise prices and expiration dates"
indirect financial
"Ownership type reported as indirect, by significant other"
exercise price financial
"Stock options show exercise price values such as 66.9700 and 53.6000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"Options to purchase shares vest on specific future dates"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

What did BIO-TECHNE (TECH) director Amy E. Herr acquire in this Form 4?

Amy E. Herr reported an indirect grant of 1,381 Restricted Stock Units on BIO-TECHNE common stock. The RSUs are held through a significant other and convert one-for-one into shares as they vest over three years starting in 2027.

How do the new RSUs for BIO-TECHNE (TECH) vest for Amy E. Herr?

The 1,381 Restricted Stock Units vest in three tranches: 460 units on 8/17/2027, 460 units on 8/17/2028, and 461 units on 8/17/2029. Each vested unit entitles the holder to receive one share of BIO-TECHNE common stock.

Were there any share sales or option exercises reported for BIO-TECHNE (TECH) in this Form 4?

No. The Form 4 shows no sales and no option exercises. It reports one RSU grant and provides updated information on existing stock options and RSU holdings, including exercise prices and expiration or vesting schedules.

What common stock holdings does Amy E. Herr report for BIO-TECHNE (TECH)?

The filing lists 2,680 shares of common stock held directly and 576 shares held indirectly through a significant other. These figures represent reported ownership positions as of the 2026-08-17 transaction date in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Herr Amy E.

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock2,680D
Common Stock576IBy significant other
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$66.97 (1)08/05/2027Common Stock4,4724,472IBy significant other
Stock Option (Right to Buy)$120.46 (1)08/06/2028Common Stock2,0762,076IBy significant other
Stock Option (Right to Buy)$94.52 (1)08/15/2029Common Stock2,1042,104IBy significant other
Stock Option (Right to Buy)$84.61 (2)08/15/2030Common Stock1,0841,084IBy significant other
Stock Option (Right to Buy)$74.91 (3)08/15/2034Common Stock1,4681,468IBy significant other
Stock Option (Right to Buy)$72.05 (1)02/03/2035Common Stock2,4152,415D
Stock Option (Right to Buy)$72.05 (4)02/03/2035Common Stock344344IBy significant other
Stock Option (Right to Buy)$53.6 (5)08/15/2035Common Stock2,7352,735IBy significant other
Stock Option (Right to Buy)$60.96 (6)10/30/2035Common Stock3,7773,777D
Restricted Stock Units(7) (8) (8)Common Stock160160IBy significant other
Restricted Stock Units(7) (9) (9)Common Stock7777IBy significant other
Restricted Stock Units(7) (10) (10)Common Stock621621IBy significant other
Restricted Stock Units(7)08/17/2026A1,381 (11) (11)Common Stock1,381$01,381IBy significant other
Explanation of Responses:
1. Fully vested.
2. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
3. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
4. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
5. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
6. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
8. 160 restricted stock units vest on 8/15/2027.
9. 38 restricted stock units vest on 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
10. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
11. 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029.
/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)